Therapy Detail

Therapy Name HER2 Vaccine
Therapy Description

A variety of ERBB2 (HER2) vaccines are under development and are designed to stimulate active immunity against tumor cells overexpressing ERBB2 (HER2) (PMID: 23585514).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
HER2 Vaccine HER2 (ERBB2) Vaccine 6 A variety of ERBB2 (HER2) vaccines are under development and are designed to stimulate active immunity against tumor cells overexpressing ERBB2 (HER2) (PMID: 23585514).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 positive stomach cancer sensitive HER2 Vaccine Preclinical - Patient cell culture Actionable In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653). 9754653
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Vaccine Phase II Actionable In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514). 23585514
Clinical Trial Phase Therapies Title Recruitment Status
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting
NCT01376505 Phase I HER2 Vaccine Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Recruiting
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting